Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)

NCT00317798 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT00317798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00317798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)
Lead sponsor
University of Rochester
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2006
Completion date
April 30, 2011
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug/agent toxicity by tissue/organ, multiple myeloma and plasma cell neoplasm